Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RARB | P10826 | 13/20 | 0.64 |
| ▸ | RARG | P13631 | 13/20 | 0.64 |
| ▸ | RARA | P10276 | 10/20 | 0.64 |
| ▸ | CYP26A1 | O43174 | 5/20 | 0.64 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.64 |
| ▸ | MEN1 | O00255 | 2/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.64 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.64 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.64 |
| ▸ | TSHR | P16473 | 1/20 | 0.64 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.64 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.64 |
| ▸ | RXRA | P19793 | 9/20 | 0.62 |
| ▸ | RXRB | P28702 | 8/20 | 0.62 |
| ▸ | PGR | P06401 | 1/20 | 0.60 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.60 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.60 |
| ▸ | BLVRB | P30043 | 1/20 | 0.60 |
| ▸ | CYP26B1 | Q9NR63 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8873094 | 0.87 | RXRA (0.67) | RARBRARGRARACYP26A1CYP3A4 | |
| SCHEMBL5080286 | 0.87 | RARB (0.71) | RARBRARGRARACYP26A1CYP3A4 | |
| SCHEMBL8102482 | 0.86 | RARB (0.64) | RARBRARGRARACYP26A1CYP3A4 | |
| SCHEMBL8093046 | 0.86 | RARB (0.64) | RARBRARGRARACYP26A1CYP3A4 | |
| SCHEMBL8102430 | 0.85 | RARB (0.62) | RARBRARGRARACYP26A1CYP3A4 | |
| SCHEMBL8100633 | 0.84 | RARB (0.61) | RARBRARGRARACYP26A1CYP3A4 | |
| SCHEMBL8100902 | 0.83 | RARB (0.60) | RARBRARGRARACYP26A1CYP3A4 | |
| SCHEMBL9282582 | 0.82 | RARB (0.69) | RARBRARGRARACYP26A1CYP3A4 | |
| SCHEMBL8839149 | 0.81 | RARB (0.45) | RARBRARGRARACYP26A1CYP3A4 | |
| SCHEMBL8102916 | 0.79 | RARB (0.51) | RARBRARGRARACYP26A1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6686386-B1 | COMBATING PHOTOINDUCED OR CHRONOLOGICAL AGEING OF SKIN WITH RETENOIC ACID RECEPTOR AGONIST | GALDERMA RESEARCH & DEVELOPMENT S.N.C. (FR) | 2004-02-03 | — | — | US | claimed |
| US-6593359-B1 | Pharmaceutical composition for increasing the rate of apoptosis in at least one cell population in which apoptosis may be induced by activating gamma -RAR receptors is disclosed. | CENTRE INTERNATIONAL DE RECHERCHES DERMATOLOGIOUES GALDERMA (C.I.R.D. GALDERMA) (FR) | 2003-07-15 | — | — | US | claimed |
| US-20010018456-A1 | Use of a RAR-gamma-specific agonist ligand for increasing the rate of apoptosis | FESUS LASZLO (HU) | 2001-08-30 | — | — | US | claimed |
| US-5556844-A | SYNERGISTIC, SKIN DISORDERS | CENTRE INTERNATIONAL DE RECHERCHES DERMATOLOGIQUES GALDERMA (CIRD GALDERMA) (FR) | 1996-09-17 | — | — | US | claimed |
| EP-0465343-B1 | Pharmaceutical or cosmetical composition comprising a retinoid and a sterol in association | CIRD GALDERMA (FR) | 1994-06-15 | — | — | EP | claimed |
| US-20210338558-A1 | USE OF COLLAGEN BINDING DOMAINS TO DELIVER PRODUCTS TO SKIN | FABIUS BIOTECHNOLOGY (US) | 2021-11-04 | — | — | US | disclosed |
| US-20080255244-A1 | Administering a Calmodulin-dependent protein kinase (M kinase II) gamma inhibitor; acute myelogenous leukemia, chronic myelogenous leukemia, gastrointestinal stromal tumor, small cell lung cancer, non-small cell lung cancer, ovarian cancer | FRED HUTCHINSON CANCER RESEARCH CENTER | 2008-10-16 | — | — | US | disclosed |
| US-20050112123-A1 | Methods of treating proteinuria | WASHINGTON, UNIVERSITY OF | 2005-05-26 | — | — | US | disclosed |
| US-6686386-B1 | COMBATING PHOTOINDUCED OR CHRONOLOGICAL AGEING OF SKIN WITH RETENOIC ACID RECEPTOR AGONIST | GALDERMA RESEARCH & DEVELOPMENT S.N.C. (FR) | 2004-02-03 | — | — | US | disclosed |
| US-6593359-B1 | Pharmaceutical composition for increasing the rate of apoptosis in at least one cell population in which apoptosis may be induced by activating gamma -RAR receptors is disclosed. | CENTRE INTERNATIONAL DE RECHERCHES DERMATOLOGIOUES GALDERMA (C.I.R.D. GALDERMA) (FR) | 2003-07-15 | — | — | US | disclosed |
| US-20030092758-A1 | Use of a RAR-gamma-specific agonist ligand for increasing the rate of apoptosis | CENTRE INTERNATIONAL DE RECHERCHES DERMATOLOGIQUES GALDERMA (C.I.R.D. GALDERMA) (FR) | 2003-05-15 | — | — | US | disclosed |
| US-6506796-B1 | Cosmetically or therapeutically treating diseases or disorders in cell populations whose pathology is linked to an inadequate rate of apoptosis by administering a therapeutically effective amount of | CENTRE INTERNATIONAL DE RECHERCHES DERMATOLOGIQUES GALDERMA (FR) | 2003-01-14 | — | — | US | disclosed |
| US-5668156-A | TREATMENT OF WARTS, ACNE, PSORIASIS, CORNEOPATHIES, KETONES | CENTRE INTERNATIONAL DE RECHERCHES DERMATOLOGIQUES GALDERMA (CIRD GALDERMA) (FR) | 1997-09-16 | — | — | US | disclosed |
| US-5597839-A | TREATMENT OF SKIN DISORDERS OR ANTIINFLAMMATORY AGENTS | CENTRE INTERNATIONAL DE RECHERCHES DERMATOLOGIQUES GALDERMA (CIRD GALDERMA) (FR) | 1997-01-28 | — | — | US | disclosed |
| US-5587367-A | SYNERGISTIC EFFECT IN TREATING SKIN DISORDERS | CENTRE INTERNATIONAL DE RECHERCHES DERMATOLOGIQUES GALDERMA (CIRD GALDERMA) (FR) | 1996-12-24 | — | — | US | disclosed |
| US-5567721-A | AROMATIC UREA COMPOUND FOR SKIN DISORDER, RHEUMATIC DISEASE, RESPIRATORY DISORDER AND EYE DISORDER | CENTRE INTERNATIONAL DE RECHERCHES DERMATOLOGIQUES (FR) | 1996-10-22 | — | — | US | disclosed |
| US-5556844-A | SYNERGISTIC, SKIN DISORDERS | CENTRE INTERNATIONAL DE RECHERCHES DERMATOLOGIQUES GALDERMA (CIRD GALDERMA) (FR) | 1996-09-17 | — | — | US | disclosed |
| US-5439925-A | Skin disorders, rheumatic diseases | CENTRE INTERNATIONAL DE RECHERCHES DERMATOLOGIQUES GALDERMA (CIRD GALDERMA) (FR) | 1995-08-08 | — | — | US | disclosed |
| US-5387594-A | Administering for topical and systemic treatment of | CENTRE INTERNATIONAL DE RECHERCHES DERMATOLOGIQUES GALDERMA (CIRD GALDERMA) (FR) | 1995-02-07 | — | — | US | disclosed |
| WO-1992006948-A1 | BI-AROMATIC COMPOUNDS AND THEIR USE IN HUMAN AND VETERINARY MEDECINE AND IN COSMETIC PREPARATIONS | CENTRE INTERNATIONAL DE RECHERCHES DERMATOLOGIQUES GALDERMA (CIRD GALDERMA) (FR) | 1992-04-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030092758-A1 | Use of a RAR-gamma-specific agonist ligand for increasing the rate of apoptosis | RARA, RARB, RARG | RARB 2/4885RARG 3/4885RARA 1/4885 |
| US-20210338558-A1 | USE OF COLLAGEN BINDING DOMAINS TO DELIVER PRODUCTS TO SKIN | COL14A1, COL2A1, COL1A1 | RARB 987/4885RARG 744/4885RARA 1211/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.